{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"11.4","upperLimit":"60.8","value":"22.2"},{"groupId":"OG001","lowerLimit":"7.7","upperLimit":"30.1","value":"22.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"19"}],"units":"Participants"}],"description":"Progression free survival time in months","dispersionType":"95% Confidence Interval","groups":[{"description":"Revlimid + rituximab with dexamethasone","id":"OG000","title":"Cohort 1"},{"description":"Revlimid + rituximab (without dexamethasone)","id":"OG001","title":"Cohort 2"}],"paramType":"MEDIAN","populationDescription":"Subjects who received both Revlimid and rituximab were evaluable for response","reportingStatus":"POSTED","timeFrame":"9 years from enrollment of first subject","title":"Time Until Progression After Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphomas With Rituximab Resistance","type":"SECONDARY","unitOfMeasure":"months"}